parametrization of effect size distributions allows insight into the structure of the genetic basis of the disease and potential subtypes, improving understanding of genotype-phenotype relationships.
Many common diseases show wide phenotypic variation.
We present a statistical method for determining whether phenotypically defined subgroups of disease cases represent different genetic architectures, in which disease-associated variants have different effect sizes in two subgroups. Our method models the genome-wide distributions of genetic association statistics with mixture Gaussians. We apply a global test without requiring explicit identification of diseaseassociated variants, thus maximizing power in comparison to standard variant-by-variant subgroup analysis. Where evidence for genetic subgrouping is found, we present methods for post hoc identification of the contributing genetic variants. We demonstrate the method on a range of simulated and test data sets, for which expected results are already known. We investigate subgroups of individuals with type 1 diabetes (T1D) defined by autoantibody positivity, establishing evidence for differential genetic architecture with positivity for thyroidperoxidase-specific antibody, driven generally by variants in known T1D-associated genomic regions.
Analysis of genetic data in human disease typically uses a binary disease model of cases and controls. However, many common human diseases show extensive clinical and phenotypic diversity, which may represent multiple causative pathophysiological processes. Because therapeutic approaches often target disease-causative pathways, understanding this phenotypic complexity is valuable for further development of treatment and the progression toward personalized medicine. Indeed, identification of patient subgroups characterized by different clinical features can aid directed therapy 1 , and accounting for phenotypic substructures can improve ability to detect causative variants by refining phenotypes into subgroups in which causative variants have larger effect sizes 2 .
Such subgroups may arise from environmental effects, reflect population variation in non-disease-related anatomy or physiology, correspond to partitions of the population in which disease heritability differs, or represent different causative pathological processes. Our method tests whether there exists a subset of disease-associated SNPs that have different effect sizes in case subgroups, determining whether heterogeneity corresponds to differential genetic pathology.
Our test is for a stronger assertion than the question of whether the subgroups of a disease group exhibit any genetic differences at all, as such differences may be entirely independent of the disease. For example, although there will be systematic genetic differences between cohorts of Asian and European patients with T1D, these differences will not generally relate to pathogenesis.
Rather than attempting to analyze SNPs individually for differences between subgroups, a task for which genome-wide association studies (GWAS) are typically underpowered, we modeled allelic differences across all SNPs using mixture multivariate normal models. This approach can give insight into the structure of the genetic basis for disease. Given evidence that there exists some subset of SNPs that both differentiate controls and cases and differentiate case subgroups, we could then reassess test statistics to search for single-SNP effects.
RESULTS

Summary of proposed method
We jointly considered allelic differences between the combined case group and controls, as well as allelic differences between case subgroups independent of controls. Specifically, we established whether the data supported a hypothesis (H 1 ) stating that a subset of SNPs associated with case-control status had different underlying effect sizes (and, hence, underlying allele frequencies) in the case subgroups. This assumption has been used previously for genetic discovery 3 .
H 1 encompasses several potential underlying mechanisms of heterogeneity. A set of SNPs may be associated with one case subgroup but not the other; the same set of SNPs may have different relative effect sizes in the subgroups or heritability may differ between the subgroups. These scenarios are discussed in the Supplementary Note.
Our overall protocol is to fit two bivariate Gaussian mixture models, which correspond to null and alternative hypotheses, to summary statistics (Z scores) derived from SNP data. We assume a group of controls and two non-intersecting case subgroups, and jointly consider allelic differences between the combined case group and the controls, as well as allelic differences between the case subgroups independent of the controls (Fig. 1) . Heterogeneity in cases can also be characterized by a quantitative trait rather than by explicit subgroups.
For a given SNP, we denote the population minor allele frequencies (MAFs) for each of the two case subgroups, the whole case group, and the control group as µ 1 and µ 2 , µ 12 , and µ c , respectively. GWAS P values for comparisons of the allelic frequency between the case subgroups and between cases and controls under the null hypotheses µ 1 = µ 2 and µ 12 = µ c are denoted as P d and P a , respectively (terms are defined similarly for quantitative heterogeneity). We then derive absolute Z scores |Z d | and |Z a | from these P values ( Fig. 1) . We consider the values |Z d | and |Z a | as absolute values of observations of random variables (Z d and Z a , respectively), which are samples from a mixture of three bivariate Gaussians. Further details are given in the Supplementary Note.
We consider each SNP to fall into one of three categories, with each category corresponding to a different joint distribution of Z d and Z a : category 1 comprises SNPs that do not differentiate case subgroups and are not associated with the phenotype as a whole (µ c = µ 1 = µ 2 ); category 2 comprises SNPs that are associated with the phenotype as a whole but that are not differentially associated with the case subgroups (µ c ≠ µ 12 ; µ 1 = µ 2 = µ 12 ); and category 3 comprises SNPs that have different population allele frequencies in the case subgroups and that may or may not be associated with the phenotype as a whole (µ 1 ≠ µ 2 ).
If the SNPs in category 3 are not associated with the disease as a whole (null hypothesis, H 0 ), then we expect Z d and Z a to be independent and the variance of Z a to be 1. If the SNPs in category 3 are also associated with the disease as a whole (alternative hypothesis, H 1 ), then the marginal variances for the joint distribution of Z d and Z a will both be greater than 1, and Z a and Z d may co-vary. Our test is therefore focused on the form of the joint distribution of Z d and Z a in category 3. Notably, we allow that the correlation between Z d and Z a may be simultaneously positive at some SNPs and negative at others. This allows for a subset of SNPs to specifically alter the risk of one case subgroup and another subset to alter the risk for the other case subgroup. To accommodate this, we only consider absolute Z scores and model the distribution of SNPs in category 3 with two mirrorimage bivariate Gaussians.
Among SNPs with the same frequency in the disease subgroups (categories 1 and 2), Z a and Z d are independent and the expected s.d. of Z d is 1. We therefore model the overall joint distribution of Z d and Z a as a Gaussian mixture in which the probability density function (PDF) of each observation (Z d ,Z a ) is given by
where N Σ (d,a) denotes the density of the bivariate normal PDF centered at 0 0       with covariance matrix Σ at (d,a). For H 0 , we have ρ = 0 and σ 3 = 1. The values π 1 , π 2 , and π 3 represent the proportion of SNPs in each category, with Σπ i = 1 ( Table 1) . Patterns of Z d and Z a for different parameter values are shown in Supplementary Table 1 .
We use the product of values of the above PDF for a set of observed Z d and Z a values as an objective function ('pseudo-likelihood' , PL) to estimate the values of the parameters. This is not a true likelihood, as observations are dependent owing to linkage disequilibrium (LD), although because we minimize the degree of LD between SNPs using
the linkage disequilibrium-adjusted kinships (LDAK) method 4 the PL is similar to a true likelihood.
Model fitting and significance testing
We fit parameters π 1 , π 2 , π 3 (= 1 − π 1 − π 2 ), σ 2 , σ 3 , τ, and ρ under H 1 and H 0 . Under H 0 , (ρ,σ 3 ) = (0,1).
We then compare the fit of the two models using the log ratio of the PLs, giving an unadjusted pseudo-likelihood ratio (uPLR). We subtract a term dependent on only Z a to minimize the influence of the Z a score distribution and add the term log(π 1 π 2 π 3 ) to ensure that the model is identifiable 5 . We term the resultant test statistic the pseudolikelihood ratio (PLR). The distribution of the PLR is minorized by a distribution of the form
where χ n 2 represents the χ 2 distribution with n degrees of freedom. The value γ arises from the weighting derived from the LDAK procedure causing a scale change in the observed PLR. The mixing parameter κ corresponds to the probability that ρ = 0 (approximately 0.5).
We estimate γ and κ by sampling random subgroups of the case group. Such subgroups only cover the subspace of H 0 with τ = 1 (no systematic allelic differences between the case subgroups), causing the asymptotic approximation of PLR by equation (2) to be poor. We thus estimate γ and κ from the distribution of a similar alternative test statistic, the cPLR (defined in the Online Methods and Supplementary Note), which is well-behaved even when τ ≈ 1 and which majorizes the distribution of PLR.
A natural next step is to search for the specific variants that contribute to the PLR. An effective test statistic for testing subgroup differentiation for single SNPs is the Bayesian conditional false discovery rate (cFDR) 6,7 applied to Z d scores 'conditioned' on Z a scores. However, this statistic alone cannot capture all the means by which the joint distribution of Z d and Z a can deviate from H 0 , and we also propose three other test statistics, each with different advantages, and compare their performance (Supplementary Note).
Power calculations, simulations, and validation of method
We tested our method by application to a range of data sets, using simulated and resampled GWAS data. First, to confirm appropriate control of type 1 error rates across H 0 , we simulated genotypes for case and control groups under H 0 for a set of 5 × 10 5 autosomal SNPs in linkage equilibrium (Supplementary Note). Quantiles for the empirical PLR distribution were smaller than those for the empirical cPLR distribution and the asymptotic mixture χ 2 , indicating that the test is conservative when τ > 1 (estimated type 1 error rate = 0.048, 95% confidence interval (CI) = 0.039-0.059) and when τ ≈1 (estimated type 1 error rate = 0.033, 95% CI = 0.022-0.045), as expected ( Fig. 2) . The empirical distribution of cPLR closely approximated the distribution of the asymptotic mixture χ 2 across all values of τ (Supplementary Note).
We then established the suitability of the test when SNPs are in LD and when genetic differences exist between subgroups that are independent of disease status overall. First, we used a data set of controls and autoimmune thyroid disease (ATD) cases and repeatedly chose case subgroups such that several SNPs had large allelic differences between the subgroups. We found good FDR control at all cutoffs (Supplementary Note), and the overall type 1 error rate at α = 0.05 was 0.041 (95% CI = 0.034-0.050). Second, we analyzed a data set of T1D cases with subgroups that were defined by geographical origin.
(2) (2) t e c h n i c a l r e p o r t s t e c h n i c a l r e p o r t s Within the UK, there is clear genetic diversity associated with region 8 . As expected, Z d scores for geographical subgroups showed inflation as compared to random subgroups ( Supplementary Fig. 1 ). None of the derived test statistics reached significance at a Bonferronicorrected threshold of P < 0.05 (minimum corrected P value > 0.8; Supplementary Fig. 2) .
To examine the power of our method, we used published GWAS data from the Wellcome Trust Case Control Consortium 9 (WTCCC), which comprised 1,994 cases of T1D, 1,903 cases of rheumatoid arthritis (RA), 1,922 cases of type 2 diabetes (T2D), and 2,953 common controls. We established that our test could differentiate between any pair of diseases considered as subgroups of a general disease case group (all P values <1 × 10 −8 ; Table 2 ).
T1D and RA have overlapping genetic bases 7, 9, 10 , as well as having non-overlapping associated regions. T1D and T2D have less genetic overlap 10 , and T2D and RA less still. This was reflected in the fitted values ( Fig. 3 and Table 2 ). The fitted values parametrizing category 2 in the full model for T1D-RA comparison (π 2 ,σ 2 ) were consistent with a subset of SNPs that were associated with case-control status (T1D + RA versus controls) but did not differentiate T1D and RA. By contrast, the parametrization of category 2 for the T1D-T2D and T2D-RA comparisons had marginal variance σ 2 ~ 1, suggesting that a subset of SNPs associated with case-control status but not with 'sub-group' status did not exist in these cases. The rejection of H 0 for these comparisons entails the existence of a set of SNPs that are associated both with case-control status and subgroup status. The H 0 model does not allow such a set of SNPs, forcing the parametrization of Z d and Z a scores for these SNPs to be 'squashed' into a category shape permitted under H 0 , with one marginal variance being 1, either in category 2 (as happens in the T2D-RA comparison because π 2 |H 0 ≈ π 3 |H 1 and σ 2 |H 0 ≈ σ 3 |H 1 ) or category 3 (as in the T1D-T2D comparison, where π 3 |H 0 ≈ π 3 |H 1 and τ|H 0 ≈ τ|H 1 ).
To determine the power of our test more generally, we showed that power depends on the number of SNPs in category 3 and on the underlying parameters of the true model, depending on the number of samples through the fitted model parameters (Supplementary Note). We therefore estimated the power of the test for varying numbers of SNPs in category 3 and for varying values of the parameters σ 3 , τ, and ρ ( Fig. 4 and Supplementary Fig. 3 ). As expected, power increased with an increasing number of SNPs in category 3, reflecting the proportion of SNPs that differentiate the case subgroups and are associated with the phenotype as a whole. Power also increased with increasing τ, σ 3 , and absolute correlation (ρ /(σ 3 τ)), as high values for these parameters enable better distinction of SNPs in categories 2 and 3.
We explored the dependence of power on sample size by subsampling the WTCCC data for RA and T1D (Fig. 4) , and we compared Figure 1 Overview of the three-category model. Left, Z d and Z a are Z scores derived from GWAS P values for allelic differences between case subgroups (1 versus 2) and between cases and controls (1 + 2 versus C), respectively. Middle, within each category of SNPs, the joint distribution of Z d and Z a has a different characteristic form. In category 1, Z scores have a unit normal distribution, and in category 2 the marginal variance of Z a can vary. The distribution of SNPs in category 3 depends on the hypothesis. Under H 0 (all disease-associated SNPs have the same effect size in both case subgroups), only the marginal variance of Z d may vary; under H 1 (subgroups correspond to differential effect sizes for disease-associated SNPs), any covariance matrix is allowed. Right, the overall SNP distribution is then a mixture of Gaussians resembling one of these two plots, but with SNP category membership unobserved. Visually, our test determines whether the observed overall Z d and Z a distribution more closely resembles the bottom than the top plot.
t e c h n i c a l r e p o r t s the power of the PLR-based test with the power to find any single SNP that differentiated the two diseases in several ways (see legend for Fig. 4 ). Although the power of the PLR-based test was limited at reduced sample sizes, it remained consistently higher than the power to detect any single SNP that differentiated the two diseases. We then repeated the analysis removing the known T1D-and RA-associated SNP rs17696736. The power to detect a SNP with significant Z d score (Bonferroni corrected) among SNPs with genome-wide significant Z a score dropped dramatically, although the power of the PLR-based test was only slightly reduced. This illustrates the robustness of the PLR test to the inclusion or removal of single SNPs with large effect sizes, a property not shared by single-SNP approaches.
Estimating power requires an estimate of the underlying values of several parameters, such as the expected total number of SNPs in the pruned data set with different population MAFs in case subgroups and the distribution of the odds ratios of such SNPs between case subgroups and between cases and controls. With sparse genomewide coverage, such as that in the WTCCC study, >1,250 cases per subgroup are necessary for 90% power (discounting the major histocompatibility complex (MHC) region). If SNP arrays with greater coverage for the disease of interest are used (such as the Immunochip for autoimmune diseases), then the values of π 3 , σ 3 , and τ are correspondingly higher and around 500-700 cases per subgroup may be sufficient.
Application to autoimmune thyroid disease and type 1 diabetes ATD takes two major forms, Graves' disease (GD; hyperthyroidism) and Hashimoto's thyroiditis (HT; hypothyroidism). The differential genetic basis of these conditions has been investigated. Detection of individual variants with different effect sizes in GD and HT is limited by sample size (particularly for HT); however, the region around TSHR (encoding thyroid-stimulating hormone receptor) shows evidence of a differential effect 11 . T1D is relatively clinically homogenous, with no major recognized subtypes, although heterogeneity arises between patients with respect to the levels of disease-associated autoantibodies and disease course differs with age at diagnosis 3 . We analyzed both of these diseases.
For ATD, we were able to confidently detect evidence for differential genetic bases for GD and HT (P = 2.2 × 10 −15 ). Fitted values are shown in Table 2 . The distribution of cPLR statistics from random subgroups agreed well with the proposed mixture χ 2 distribution (Supplementary Fig. 4) .
For T1D, we considered four subgroupings defined by plasma levels of the T1D-associated autoantibodies thyroid peroxidase antibody (TPO-Ab; n = 5,780), insulinoma-associated antigen 2 antibody Parameters τ, σ 2 , and σ 3 are dependent on sample sizes but can be converted to sample-size-independent forms (supplementary note). We tested each of the subgroupings while retaining and excluding the MHC region. Fitted values for models with and without the MHC region are shown in Supplementary Table 2 , and plots of Z a and Z d scores are shown in Supplementary Figure 5 . By retaining the MHC region, we were able to confidently reject H 0 for subgroupings based on positivity for TPO-Ab, IA-2Ab, and GAD-Ab (all P values <1.0 × 10 −20 ). Although there was evidence that SNPs in the data set were associated with PCA-Ab positivity (τ ≈ 2.5, null model), the improvement in fit in the full model was not significant, and we conclude that such SNPs determining PCA-Ab status are not in general associated with T1D. This can be seen in the plot of Z a against Z d (Supplementary Fig. 5 ), in which SNPs with high Z d values do not have higher-than-expected Z a values.
With the MHC region removed, the subgrouping based on TPO-Ab positivity was significantly better fit by the full model (P = 1.5 × 10 −4 ). There was weaker evidence to reject H 0 for GAD-Ab (P = 0.002) and IA2-Ab (P = 0.008) (Bonferroni-corrected threshold at α < 0.05 of 0.006). The fitted values of τ in both the full and null models for GAD-Ab were ~1, indicating an absence of evidence for a category of non-MHC T1D-associated SNPs that are additionally associated with GAD-Ab positivity. Collectively, these findings indicate that the differential genetic basis for T1D with GAD-Ab versus IA2-Ab positivity is driven principally by the MHC region; although PCA-Ab status is partially genetically determined, the set of causative variants is independent of T1D-causative pathways.
The variation in genetic architecture of T1D with age is not fully understood, but previous studies have suggested larger observed effects at known loci in patients who were diagnosed at a younger age [12] [13] [14] [15] .
We investigated whether these differences are indicative of widespread differences in variant effect sizes dependent on age at diagnosis, possibly due to differential heritability (Supplementary Note). We applied the method to the T1D data set with Z d defined by age at diagnosis (quantitative trait). Fitted values are shown in Supplementary Table 3 , and Z a and Z d scores are shown in Supplementary Figure 6 . Hypothesis H 0 could be rejected confidently when retaining or removing the MHC region (P < 1.0 × 10 −20 and P = 0.007, respectively). Signed Z d and Z a scores for age at diagnosis showed a visible negative correlation (r g method 2; P = 0.002) among Z d and Z a scores for disease-associated SNPs (Fig. 5) . This is consistent with higher genetic liability with lower age at diagnosis.
Assessment of individual SNPs
Many SNPs that discriminated subgroups were in known diseaseassociated regions (Supplementary Tables 4-6) . In several cases, our method identified disease-associated SNPs that have reached genomewide significance in subsequent larger studies, but for which the Z a score in the WTCCC study was not near significance. For example, SNP rs3811019, in the PTPN22 (protein tyrosine phosphatase, nonreceptor type 22) region, was identified as likely to discriminate between T1D and T2D (P = 3.046 × 10 −6 ; Supplementary Table 5 ), despite a P value of 3 × 10 −4 for joint T1D-T2D association.
For GD and HT, SNPs near the known ATD-associated loci PTPN22 (rs7554023), CTLA4 (rs58716662), and CEP128 (rs55957493) were identified as likely to contribute to the difference in genetic basis for these diseases (Supplementary Table 7) . SNPs rs34244025 and rs34775390 are not known to be associated with ATD but are in known loci for inflammatory bowel disease and ankylosing Figure 4 The power of PLR testing to reject H 0 (genetic homogeneity between case subgroups) depends on the number of SNPs in category 3 and the underlying values of model parameters σ 2 , σ 3 , τ, and ρ. Power is dependent on the number of case and control samples through the magnitudes of σ 3 and τ (supplementary note). Left, power estimates for various values of π 3 , σ 3 , τ, and ρ. N is the approximate number of SNPs in category 3 (∝π 3 ). Each simulation was on 5 × 10 4 simulated autosomal SNPs in linkage equilibrium. ρ (σ 3 × τ) is the absolute correlation between Z a and Z d in category 3 (also see supplementary Fig. 3) . Right, the power of PLR testing to detect differences in the genetic basis of the T1D and RA subgroups of a combined autoimmune data set, downsampling to varying numbers of cases (x axis). The power for PLR testing is compared with the power to find ≥1 SNP with a Z d score reaching genome-wide significance (GWS; P ≤ 5 × 10 −8 ) or Bonferroni-corrected significance (BCS; P ≤ 0.05/(total number of SNPs)) and the power to detect any SNP with a Z a score reaching genome-wide significance and a Z d score reaching Bonferroni-corrected significance (sub-BCS; P ≤ 0.05/(total number of SNPs with a Z a score reaching genome-wide significance)). Error bars show 95% confidence intervals. Circles and solid lines for each color show power for all SNPs; triangles and dotted lines show power for all SNPs except rs17696736. Power for the sub-BCS approach drops dramatically but power for PLR testing is not markedly affected when rs17696736 is excluded, indicating the relative robustness of PLR testing to single-SNP effects.
t e c h n i c a l r e p o r t s spondylitis, and our data suggest that they may differentiate between GD and HT (FDR = 0.003).
We searched for non-MHC SNPs with differential effect sizes with TPO-Ab positivity in T1D, the subgrouping of T1D for which we could most confidently reject H 0 . Previous work 3 identified several loci potentially associated with TPO-Ab positivity by restricting the focus to known T1D loci, enabling use of a larger data set than was available to us. We list the top ten SNPs for each summary statistic for TPO-Ab positivity in Supplementary Table 8 . Subgroup-differentiating SNPs included several near known T1D-associated loci, such as CTLA4 (rs7596727), BACH2 (rs11755527), RASGRP1 (rs16967120), and UBASH3A (rs2839511) 16 . These loci agreed with those found by Plagnol et al. 3 , but our analysis used the available genotype data only, without external information on confirmed T1D-related loci. We were not able to replicate the same P values owing to reduced sample numbers.
Finally, we analyzed non-MHC SNPs with varying effect sizes with age at diagnosis in T1D ( Supplementary Table 9 ). This analysis implicated SNPs in or near CTLA4 (rs2352551), IL2RA (rs706781), and IKZF3 (rs11078927).
DISCUSSION
The problem we address is part of a wider aim of adapting GWAS to complex disease phenotypes. As the body of GWAS data grows, the analysis of between-disease similarity and within-disease heterogeneity has led to substantial insight into shared and distinct disease pathology 2, 6, 7, 17, 18 . We sought here to use genomic data to infer whether such disease subtypes exist. Our problem is related to the question of whether two different diseases share any genetic basis 19 but differs in that the implicit null hypothesis relates to genetic homogeneity between case subgroups rather than to genetic independence of separate diseases.
Our test strictly assesses whether a set of SNPs have different effect sizes in case subgroups. We interpret this as 'differential causative pathology' , which encompasses several disease mechanisms (discussed in the Supplementary Note). In some cases, if subgroups are defined on the basis of the presence or absence of a known disease risk factor, then the heritability of the disease will differ between subgroups, with corresponding changes in variant effect sizes.
We preferentially use 'absolute covariance' ρ ( Supplementary Table 1 ) because we expect that Z a and Z d will frequently co-vary positively and negatively at different SNPs in the same analysis; for instance, some variants may be deleterious only for subgroup 1 and others may be deleterious only for subgroup 2. A potential advantage of our symmetric model is the potential to generate Z d scores from analysis of variance (ANOVA)-style tests for genetic homogeneity between three or more subgroups, in which case-reconstructed Z scores would be directionless.
Etiologically and genetically heterogeneous subgroups within a case group correspond to substructures in the genotype matrix. Information about such substructures is lost in a standard GWAS, which uses only the column sums (MAFs) of the matrix (linear-order information). Data-driven selection of appropriate case subgroups and corresponding analyses of these subgroups can use more of the remaining quadratic-order information the matrix contains. Indeed, a 'two-dimensional' GWAS approach (using Z a and Z d ) instead of a standard GWAS (using only Z a ) may improve SNP discovery, as we found for PTPN22 in RA-T2D comparison. However, this can only be the case if the subgroups correspond to different variant effect sizes; for other subgroupings, a two-dimensional GWAS will only add noise.
Although it seems appealing to use this method to search for some 'optimal' partition of patients, we prefer to focus on testing subgroupings derived from independent clinical or phenotypic data. First, it is difficult to characterize subgroupings as 'better' or 'worse' , and no one parameter can parametrize the degree to which two subgroups differ; parameters π 3 , τ, and ρ all contribute, and attempts to test the hypothesis using a single measure (such as genetic correlation) have serious shortcomings (Supplementary Note). Second, even if subgroups could meaningfully be ranked, the search space of the potential subgroupings of a case group is prohibitively large (2 N for N cases), making exhaustive searches difficult.
We demonstrated that the effect sizes of T1D-causative SNPs differ with age at disease diagnosis. The strong negative correlation observed (Fig. 5) is consistent with an increased total genetic liability in samples with an earlier age of diagnosis, a finding supported by candidate gene studies [13] [14] [15] and epidemiological data 12 . Such a pattern arises naturally from a liability-threshold model, in which total liability depends additively on both genetic effects and environmental influences that accumulate with age (Supplementary Note).
Our method necessarily dichotomizes the multitude of mechanisms of heterogeneity, although there are many diverse forms ( Supplementary Table 1 and Supplementary Note) . There is potential to further dissect the mechanisms of disease heterogeneity by incorporating estimations of genetic correlation 19 or assessing evidence for liability-threshold models 20 . Similar mixture Gaussian approaches may also be adaptable to this purpose, by assessing other families of effect size distributions.
Our method adds to the current body of knowledge by extracting additional information from a disease data set in comparison to a standard GWAS analysis and determines whether further analysis of disease pathogenesis in subgroups is justified. Our approach is analogous to the intuitive method of searching for between-subgroup differences in SNPs with known disease associations 3 , but it does not restrict focus to strong disease associations, enabling use of information from disease-associated SNPs that do not reach significance. Our
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Joint distribution of variables Z a and Z d . We assume that SNPs may be divided into three categories, as described in the Results section ( Fig. 1) . Under these assumptions, Z a and Z d scores have the joint PDF given by equation (1). We define Θ as the vector of values π 1 , π 2 , π 3 , τ, σ 2 , σ 3 , and ρ. Z scores Z a and Z d are reconstructed from GWAS P values for SNP associations. In practice, because our model is symmetric, we only require absolute Z scores, without considering effect direction. For sample sizes n 1 and n 2 , and 97.5% odds ratio quantile α, the expected observed s.d. of Z scores (i.e., σ 2 , σ 3 , and τ) is given by Note) .
Definition and distribution of PLR statistics. For a set of observed Z scores Z = (Z a ,Z d ), we define the joint unadjusted pseudo-likelihood PL da (Z | Θ) as
where the term C log(π 1 π 2 π 3 ) is included to ensure the identifiability of the model 5 and weights w i are included to adjust for LD (see below). We now set The empirical distribution of uPLR may substantially majorize the asymptotic distribution when τ ≈ 1. In the full model, the marginal distribution of Z a has more degrees of freedom (four; π 1 , π 2 , σ 2 , and σ 3 ) than it does under the null model (two; π 2 and σ 2 , as σ 3 ≡ 1). This can mean that certain distributions of Z a can drive high values of uPLR independent of the values of Z d (Supplementary Note) , which is unwanted as the Z a values reflect only case-control association and carry no information about case subgroups. If observed uPLRs from random subgroups (for which τ = 1 by definition) are used to approximate the null uPLR distribution, then this effect would lead to serious loss of power when τ >> 1.
This effect can be managed by subtracting a correcting factor based on the pseudo-likelihood of Z a alone, which reflects the contribution of Z a values to the uPLR. We define
that is, the marginal likelihood of Z a . Given q 1  , q 0  as defined above, we define
We now define the PLR as
The action of f(Z a ) leads to the asymptotic distribution of PLR slightly minorizing the asymptotic mixture χ 2 distribution of uPLR to differential degrees dependent on the value of τ (Supplementary Note) .
We define the similar test statistic cPLR as The empirical distribution of cPLR for random subgroups majorizes the empirical distribution of PLR (Supplementary Note). Furthermore, the approximation of the empirical distribution of cPLR by its asymptotic distribution is good across all values of τ; i.e., across the whole null hypothesis space.
Our approach is to compare the PLR of a test subgroup to the cPLR of random subgroups, which constitutes a slightly conservative test under the null hypothesis (Supplementary Note).
Allowance for linkage disequilibrium. The asymptotic approximation of the pseudo-likelihood ratio distribution breaks down when values of Z a and Z d are correlated because of LD. One way to overcome this is to 'prune' SNPs by hierarchical clustering until only those with negligible correlation remain. A disadvantage with this approach is that it is difficult to control which SNPs are retained in an unbiased way without risking removal of SNPs that contribute greatly to the difference between subgroups.
We opted to use the LDAK algorithm 4 , which assigns weights to SNPs that approximately correspond to their 'unique' contribution. Using ρ ij to denote the correlation between SNPs i and j, and using d(i,j) to denote their chromosomal distance, the weights w i are computed so that This approach has the advantage that, if n SNPs are in perfect LD and not in LD with any other SNPs, then each will be weighted 1/n, reducing the overall contribution to the likelihood to that of one SNP. In practice, the linear programming approach results in many SNP weights being 0. Using the LDAK algorithm therefore allows more SNPs to be retained and to contribute to the model than would be retained in a pruning approach.
A second advantage of LDAK is that it homogenizes the contribution of each genome region to the overall pseudo-likelihood. Many modern microarrays fine map areas of the genome known or suspected to be associated with traits of interest 22 , which could theoretically lead to peaks in the distribution of SNP effect sizes, disrupting the assumption of normality. LD pruning and LDAK both reduce this effect by homogenizing the number of tags in each genomic region.
We adapted the pseudo-likelihood function to the weights by multiplying the contribution of each SNP to the log likelihood by its weight (equation (4)), essentially counting the ith SNP w i times over. Adjusting using LDAK was effective in enabling the distributions of PLR to be well approximated by mixture χ 2 distributions of the form in equation (2) (Supplementary Fig. 4 ).
Expectation-maximization algorithm to estimate model parameters.
We use an expectation-maximization algorithm 23, 24 to fit maximum-PL parameters. Given an initial estimate of parameters 
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the potential advantage of characterizing heterogeneity using a single widely interpretable metric. This may be between Z scores derived from comparing the control group to each case subgroup, testing under the null hypothesis r g = 1 (method 1) or between the familiar Z a and Z d , under the null hypothesis r g = 0 (method 2). We explore these methods in the Supplementary Note. We show that method 1 leads to systematically high false positive rates, as r g is also reduced from 1 in subgroupings that are independent of the overall disease process (for example, hair color in T2D). We show that method 2 is considerably less powerful than our method because it tests a narrower definition of H 1 , which does not take account of the marginal variances of the distribution of Z d ,Z a in category 3 and requires that correlation between Z d and Z a be always positive or always negative, in contrast to our symmetric model (Fig. 1) . Indeed, parameter ρ estimates an analog of r g to account for simultaneous correlation and anticorrelation.
Methods to compute r g were not explicitly proposed as a method for subgroup testing, and our analysis does not indicate any general shortcomings. However, comparison with r g -based approaches places our method in the context of established methodology, demonstrating the necessity of considering both variance parameters (τ and σ 3 ) and covariance parameters (ρ) in testing a subgrouping of interest.
Description of GWAS data sets. ATD samples were genotyped on the Immunochip 22 , a custom genotyping array targeting putative autoimmunityassociated regions. Data were collected for GWAS-like analyses of dense SNP data 11 . The data set comprised 2,282 cases of Graves' disease, 451 cases of Hashimoto's thyroiditis and 9,365 controls.
T1D samples, which were gathered for a GWAS on T1D 16 , were genotyped on either the Illumina 550K or Affymetrix 500K platform. We imputed between platforms in the same way as that for the original GWAS. The data set comprised genotypes from 5,908 T1D cases and 8,825 controls, of which all had measured TPO-Ab values, 3,197 had measured IA2-Ab values, 3,208 had measured GAD-Ab values and 2,240 had measured PCA-Ab values. Comparisons for each autoantibody were made between cases positive for that autoantibody and cases not positive for it. We did not attempt to perform comparisons of individuals who were positive for different autoantibodies (for instance, TPO-Ab positive versus IA2-Ab positive) because many individuals were positive for both.
To generate summary statistics corresponding to geographical subgroups, we considered the subgroup of cases from each of 12 regions and each pair of regions against all other cases (78 subgroupings in total). To maximize sample sizes, we considered T1D cases as 'controls' and split the control group into subgroups.
Quality control. Particular care had to be taken with quality control, as Z scores had to be relatively reliable for all SNPs assessed rather than just those putatively reaching genome-wide significance. For the comparisons between data from T1D, T2D and RA cases, which we reused from the WTCCC, a critical part of the original quality control procedure was visual analysis of cluster plots for SNPs reaching significance, and systematic quality control measures based on differential call rates and deviance from Hardy-Weinberg equilibrium were correspondingly loose 9 . Given that we were not searching for individual SNPs, this was clearly not appropriate for our method.
We retained the original call rate (CR) and MAF thresholds (MAF ≥ 1%, CR ≥ 95% if MAF ≥ 5%, CR ≥ 99% if MAF < 5%) but used a stricter control on Hardy-Weinberg equilibrium, requiring P ≥ 1 × 10 −5 for deviation from Hardy-Weinberg equilibrium in controls. We also required that deviance from Hardy-Weinberg equilibrium in cases satisfied P ≥ 1.91 × 10 −7 , corresponding to |z| ≤ 5. The looser threshold for Hardy-Weinberg equilibrium in cases was chosen because deviance from Hardy-Weinberg equilibrium can arise because of true SNP effects 27 . We also required that the call rate difference not be significant (P ≥ 1 × 10 −5 ) between any two groups, including case-case and case-control differences. Geographical data were collected by the WTCCC and consisted of assignment of samples to one of 12 geographical regions (Scotland, northern Ridings, northwestern Ridings, east Ridings, west Ridings, North Midlands, Midlands, Wales, eastern England, southern England, southeastern England and London 9 ). In analyzing differences between autoimmune diseases, we stratified by geographical location; when assessing subgroups on the basis of geographical location, we did not.
For the ATD and T1D data, we used quality control procedures identical to those used in the original papers 11, 16 . We applied genomic control 28 to computation of Z a and Z d scores, except for in our analysis of ATD (following the original authors 11 ) and our geographical analyses (as discussed above). In all analyses, except where otherwise indicated, we removed the MHC region with a wide margin (~5 Mb on either side).
Code availability. Code is available from https://github.com/jamesliley/subtest (R package). Data availability. This paper reanalyzes previously published data sets. WTCCC data access for T1D, T2D, RA and controls 9 is described at https:// www.wtccc.org.uk/info/access_to_data_samples.html. ATD data are available upon request from the authors of the original study 11 . T1D genetic data from ref. 16 are available at the database of Genotypes and Phenotypes (dbGaP) under accession phs000180.v3.p2, which we combined with autoantibody data available from the study authors 3 .
